Details

<p><i>List of Contributors, x</i></p> <p><i>Preface, xxi</i></p> <p><b>Section 1 Malignant Hematology and Hematopoietic Cell Transplantation</b></p> <p><b>Part 1 Acute Lymphoblastic Leukemia in Adults</b></p> <p>1 Diagnosis of acute lymphoblastic leukemia, 5<br /> <i>Frederick G. Behm, Agatha Bogard, Syed A. Abutalib, and Sujata S. Gaitonde</i></p> <p>2 Prognostic markers and models in acute lymphoblastic leukemia, 18<br /> <i>Dieter Hoelzer</i></p> <p>3 Management of B-cell acute lymphoblastic leukemia, 22<br /> <i>Hady Ghanem, Hagop Kantarjian, Nitin Jain, and Elias Jabbour</i></p> <p>4 Management of T-cell acute lymphoblastic leukemia, 29<br /> <i>Daniel J. DeAngelo</i></p> <p>5 Minimal residual disease in acute lymphoblastic leukemia, 35<br /> <i>Meir Wetzler</i></p> <p>6 Hematopoietic cell transplantation in adult acute lymphoblastic leukemia, 40<br /> <i>Netanel A. Horowitz and Jacob M. Rowe</i></p> <p><b>Part 2 Acute Myeloid Leukemia in Adults</b></p> <p>7 Prognosis in acute myeloid leukemia: cytogenetics and beyond, 51<br /> <i>Gordana Raca, Madina Sukhanova, and Lucy A. Godley</i></p> <p>8 Induction therapy in acute myeloid leukemia, 58<br /> <i>Tapan Kadia and Farhad Ravandi</i></p> <p>9 Consolidation therapy in acute myeloid leukemia, 67<br /> <i>Gregory K. Behbehani and Bruno C. Medeiros</i></p> <p>10 Management of acute promyelocytic leukemia, 71<br /> <i>Eytan M. Stein and Martin S. Tallman</i></p> <p>11 Minimal residual disease in acute myeloid leukemia, 76<br /> <i>Hans Beier Ommen, Line Nederby, Marie Toft-Petersen, Charlotte Guldborg Nyvold, and Peter Hokland</i></p> <p>12 Relapsed and refractory acute myeloid leukemia, 82<br /> Stefan H. Faderl</p> <p>13 Hematopoietic cell transplantation in acute myeloid leukemia, 89<br /> <i>Antonio M. Jimenez and Stefan O. Ciurea</i></p> <p><b>Part 3 Myelodysplastic Syndromes and Related Disorders</b></p> <p>14 Pitfalls in the diagnosis of myelodysplastic syndromes, 99<br /> <i>Jay Yang, Gail Bentley, and Charles A. Schiffer</i></p> <p>15 Cytogenetics and prognostic models in myelodysplastic syndromes, 106<br /> <i>Uma Borate and Harry P. Erba</i></p> <p>16 Management of myelodysplastic syndromes, 113<br /> <i>Vu H. Duong, Alan F. List, and Rami S. Komrokji</i></p> <p>17 Management of therapy-related myeloid neoplasms, 120<br /> <i>Jagoda K. Jasielec and Richard A. Larson</i></p> <p>18 Hematopoietic cell transplantation in myelodysplastic syndromes, 126<br /> <i>Antonio Di Stasi, Armin Ghobadi, and Partow Kebriaei</i></p> <p>19 Acquired aplastic anemia, 131<br /> <i>Valeria Visconte and Ramon V. Tiu</i></p> <p><b>Part 4 Myeloproliferative Neoplasms</b></p> <p>20 Diagnostic approach in myeloproliferative neoplasms, 137<br /> <i>Ayalew Tefferi</i></p> <p>21 Chronic myeloid leukemia: chronic phase, 142<br /> <i>Jerald P. Radich</i><br /> <br /> 22 Blast crisis of chronic myeloid leukemia, 147<br /> <i>Michael J. Mauro</i></p> <p>23 Chronic myeloid leukemia and pregnancy, 150<br /> <i>Michael J. Mauro</i></p> <p>24 Polycythemia vera, 152<br /> <i>Constantine S. Tam and Srdan Verstovsek</i></p> <p>25 Essential thrombocytosis, 156<br /> <i>Paola Guglielmelli and Alessandro M. Vannucchi</i></p> <p>26 Primary myelofibrosis, 162<br /> <i>Ayalew Tefferi</i></p> <p>27 Eosinophilic myeloproliferative disorders, 167<br /> <i>Jason Gotlib</i></p> <p>28 Chronic myelomonocytic leukemia, 176<br /> <i>Mrinal M. Patnaik</i></p> <p>29 Hematopoietic cell transplantation in chronic myeloid leukemia, 180<br /> <i>Jerald P. Radich</i></p> <p>30 Hematopoietic cell transplantation in primary myelofibrosis, 187<br /> <i>Irum Khan and Damiano Rondelli</i></p> <p><b>Part 5 Chronic Lymphocytic and Other Leukemias</b></p> <p>31 Prognostic markers and management of chronic lymphocytic leukemia, 195<br /> <i>Courtney D. DiNardo and Susan O’Brien</i></p> <p>32 Hematopoietic cell transplantation in chronic lymphocytic leukemia, 201<br /> <i>Michael R. Bishop</i></p> <p>33 Prolymphocytic leukemia, 207<br /> <i>Claire Dearden</i></p> <p>34 Hairy cell leukemia, 220<br /> <i>Justin M. Watts and Martin S. Tallman</i></p> <p><b>Part 6 Hodgkin Lymphoma</b></p> <p>35 Management of classical Hodgkin lymphoma, 229<br /> <i>Kristen Sanfi lippo and Nancy L. Bartlett</i></p> <p>36 Nodular lymphocyte-predominant Hodgkin lymphoma, 235<br /> <i>Dennis A. Eichenauer</i></p> <p>37 Hematopoietic cell transplantation in Hodgkin lymphoma, 240<br /> <i>Tsiporah Shore and Koen van Besien</i></p> <p><b>Part 7 Non-Hodgkin’s Lymphomas</b></p> <p>38 Pitfalls in the diagnosis of non-Hodgkin’s lymphomas, 247<br /> <i>Carmen Barcena and Laurence de Leval</i></p> <p>39 Follicular lymphoma, 257<br /> <i>Myron S. Czuczman</i></p> <p>40 Diffuse large B-cell lymphoma, 263<br /> <i>Andrew D. Zelenetz</i></p> <p>41 Mantle cell lymphoma, 270<br /> <i>Stephen Smith and John Sweetenham</i></p> <p>42 Marginal zone lymphoma, 275<br /> <i>Sarah Rutherford, Wayne Tam, and Peter Martin</i></p> <p>43 Primary mediastinal large B-cell lymphoma, 282<br /> <i>Pier Luigi Zinzani</i></p> <p>44 Burkitt lymphoma, 286<br /> <i>Mark Roschewski and Wyndham Wilson</i></p> <p>45 Gray zone lymphoma, 290<br /> <i>Caron A. Jacobson and Ann S. LaCasce</i></p> <p>46 Transformed lymphoma, 295<br /> <i>Stephane Doucet and Jane N. Winter</i></p> <p>47 HIV-associated lymphoma, 304<br /> <i>Kieron Dunleavy</i></p> <p>48 Primary CNS lymphoma, 308<br /> <i>Nicholas A. Blondin, Joachim M. Baehring, and Fred H. Hochberg</i></p> <p>49 Primary cutaneous lymphoma, 316<br /> <i>Thomas M. Habermann</i></p> <p>50 Mycosis fungoides and Sézary syndrome, 323<br /> <i>Stephane Dalle, Marie Perier-Muzet, Brigitte Balme, and Luc Thomas</i></p> <p>51 Hematopoietic cell transplantation in indolent non-Hodgkin’s lymphoma, 327<br /> <i>Saurabh Chhabra and Ginna G. Laport</i></p> <p>52 Hematopoietic cell transplantation in diffuse large B-cell lymphoma, 332<br /> <i>Syed A. Abutalib and Istvan Redei</i></p> <p>53 Hematopoietic cell transplantation in T-cell non-Hodgkin’s lymphomas, 339<br /> <i>Lori S. Muffly and Sonali M. Smith</i></p> <p><b>Part 8 Plasma Cell Neoplasms and Related Disorders</b></p> <p>54 Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance, 347<br /> <i>Robert A. Kyle</i></p> <p>55 Risk stratification and response assessment in multiple myeloma and Waldenström’s macroglobulinemia, 352<br /> <i>Silvia Gentili and Sagar Lonial</i></p> <p>56 Treatment of multiple myeloma, 358<br /> <i>Cindy Varga, Claudia Paba Prada, Kenneth Anderson, and Paul Richardson</i></p> <p>57 Light-chain amyloidosis, 366<br /> <i>David C. Seldin</i></p> <p>58 Waldenström’s macroglobulinemia, 371<br /> <i>Anita D’Souza and Morie A. Gertz</i></p> <p>59 Autologous hematopoietic cell transplantation in multiple myeloma, 376<br /> <i>Jean-Luc Harousseau and Mohamad Mohty</i></p> <p>60 Allogeneic hematopoietic cell transplantation in multiple myeloma, 381<br /> <i>Jasleen Randhawa, Veerpal Singh, and Parameswaran Hari</i></p> <p><b>Part 9 Special Issues in Hematology</b></p> <p>61 Role of PET scan in lymphomas, 391<br /> <i>Matthew A. Lunning and James O. Armitage</i></p> <p>62 Radioimmunotherapy in lymphomas, 398<br /> <i>Reem Karmali and Stephanie A. Gregory</i></p> <p>63 Radiation oncology consultation for hematologic malignancies, 403<br /> <i>Chris R. Kelsey and Leonard R. Prosnitz</i></p> <p><b>Part 10 Special Issues in Hematopoietic Cell Transplantation</b></p> <p>64 Donor and graft selection in allogeneic hematopoietic cell transplantation, 411<br /> <i>Jose Leonel Ochoa-Bayona and Claudio Anasetti</i></p> <p>65 Preparative regimens in allogeneic hematopoietic cell transplantation for malignant hematological<br /> diseases, 417<br /> <i>Robert J. Soiffer</i></p> <p>66 T-cell depletion in allogeneic hematopoietic cell transplantation, 421<br /> <i>Jenna D. Goldberg and Miguel-Angel Perales</i></p> <p>67 Prevention and treatment of relapse following hematopoietic cell transplantation, 426<br /> <i>Robert Chen, Sandra Thomas, and Stephen J. Forman</i></p> <p>68 Acute graft-versus-host disease, 432<br /> <i>Andrew C. Harris and John E. Levine</i></p> <p>69 Chronic graft-versus-host disease, 438<br /> <i>Carrie L. Kitko and Daniel R. Couriel</i></p> <p><b>Section 2 Oncology</b></p> <p><b>Part 1 Central Nervous System Tumors</b></p> <p>70 Primary brain tumors, 449<br /> <i>Barbara J. O’Brien and Mark R. Gilbert</i></p> <p>71 Secondary brain and spinal cord tumors, 457<br /> <i>Rimas V. Lukas, Patrik Gabikian, and Steven J. Chmura</i></p> <p><b>Part 2 Head and Neck Cancers and Thoracic Malignancies</b></p> <p>72 Medical management of head and neck cancers, 467<br /> <i>Tobenna Nwizu and David Adelstein</i></p> <p>73 Endocrine malignancies, 476<br /> <i>Ann W. Gramza</i></p> <p>74 Methodological and practical challenges for personalized therapies in non-small-cell lung cancer, 480<br /> <i>Ignacio I. Wistuba</i></p> <p>75 Screening, staging, and stage I non-small-cell lung cancer, 486<br /> <i>Tarek M. Mekhail</i></p> <p>76 Stage II and III non-small-cell lung cancer, 493<br /> <i>Grzegorz Korpanty and Natasha B. Leighl</i></p> <p>77 Recurrent and metastatic non-small-cell lung cancer and novel targets, 500<br /> <i>Evan Pisick and Ravi Salgia</i></p> <p>78 Small-cell lung cancer, 503<br /> <i>Stephen V. Liu and Glen J. Weiss</i></p> <p>79 Mesothelioma, 506<br /> <i>Christopher W. Towe and Harvey I. Pass</i></p> <p><b>Part 3 Breast Cancer</b></p> <p>80 Immunohistochemistry testing and beyond in breast cancer, 515<br /> <i>Alejandro A. Gru and D. Craig Allred</i></p> <p>81 Prevention and adjuvant therapy in breast cancer, 523<br /> <i>Faithlore P. Gardner and Edith A. Perez</i></p> <p>82 Preoperative systemic therapy for breast cancer, 532<br /> <i>Virginia Kaklamani and William J. Gradishar</i></p> <p>83 Recurrent and metastatic breast cancer, 540<br /> <i>Dennis L. Citrin</i></p> <p>84 Special issues in the young and pregnant patient with breast cancer, 546<br /> <i>Hatem A. Azim Jr. and Fedro A. Peccatori</i></p> <p><b>Part 4 Gastrointestinal Oncology</b></p> <p>85 Early-stage esophageal and stomach cancers, 555<br /> <i>M. Naomi Horiba and Yixing Jiang</i></p> <p>86 Metastatic esophagogastric cancer: controversies, consensus, and new targets, 562<br /> <i>Geoffrey Y. Ku and David H. Ilson</i></p> <p>87 Early-stage colorectal cancer, 567<br /> <i>Vaibhav Sahai and Al B. Benson III</i></p> <p>88 Recurrent and metastatic colorectal cancer: controversies, consensus, and new targets, 573<br /> <i>Davendra Sohal and Robert J. Pelley</i></p> <p>89 Pancreatic cancer, 581<br /> <i>Katherine Van Loon and Margaret Tempero</i></p> <p>90 Hepatobiliary cancer, 590<br /> <i>Keith Stuart</i></p> <p>91 Neuroendocrine tumors, 595<br /> <i>Anya Litvak and Leonard Saltz</i></p> <p>92 Transarterial liver-directed therapies in oncology, 601<br /> <i>Divyesh G. Mehta and Jeffery Choh</i></p> <p>93 Anal cancer, 606<br /> <i>Rob Glynne Jones</i></p> <p><b>Part 5 Genitourinary Oncology</b></p> <p>94 Renal cancer: tumor diversity, molecular taxonomy, and prognostic algorithms, 615<br /> <i>Henry J. Conter and Eric Jonasch</i></p> <p>95 Medical management of renal cancer, 621<br /> <i>Gary R. MacVicar and Timothy M. Kuzel</i></p> <p>96 Medical management of bladder cancer, 628<br /> <i>Gary R. MacVicar and Timothy M. Kuzel</i></p> <p>97 Prostate cancer: Screening, surveillance, prognostic algorithms and independent pathologic predictive<br /> parameters, 634<br /> <i>Megan G. Lockyer and Thomas M. Wheeler</i></p> <p>98 Medical management of prostate cancer, 638<br /> <i>Elizabeth K. O’Donnell and Philip Kantoff</i></p> <p>99 Germ cell tumors, 645<br /> <i>Timothy Gilligan</i></p> <p><b>Part 6 Skin Malignancies</b></p> <p>100 Medical management of melanoma, 653<br /> <i>Ana M. Ciurea and Kim Margolin</i></p> <p>101 Nonmelanoma skin cancers, 661<br /> <i>Daniel Christiansen and Anna Sancho Clayton</i></p> <p><b>PART 7 Gynecological Malignancies</b></p> <p>102 Ovarian cancer: neoadjuvant, adjuvant, and surgical issues, 669<br /> <i>Alpa M. Nick and Robert L. Coleman</i></p> <p>103 Ovarian cancer: second-line treatment strategies, 675<br /> <i>Maurie Markman</i></p> <p>104 Endometrial and cervical cancers, 681<br /> <i>Maurie Markman</i></p> <p><b>PART 8 Sarcomas</b></p> <p>105 Bone sarcomas, 689<br /> <i>Nicole Larrier, William C. Eward, and Richard F. Riedel</i></p> <p>106 Soft tissue sarcomas, 696<br /> <i>Neeta Somaiah and Shreyaskumar Patel</i></p> <p><b>PART 9 Multidisciplinary Approach: Consultation with Surgical Oncology Team</b></p> <p>107 Surgical aspects of head and neck cancers, 707<br /> <i>Constance E.H. Teo and Randal S. Weber</i></p> <p>108 Surgical aspects of thoracic malignancies, 711<br /> <i>Albert S.Y. Chang, Thomas A. D’Amico, and David C. White</i></p> <p>109 Surgical aspects of upper gastrointestinal cancers, 719<br /> <i>Sabha Ganai and Mitchell C. Posner</i></p> <p>110 Surgical aspects of pancreatic cancer, 723<br /> <i>Amanda B. Cooper, Ching-Wei D. Tzeng, and Matthew H.G. Katz</i></p> <p>111 Surgical aspects of hepatobiliary tumors, 729<br /> <i>Subhasis Misra and Leonidas Koniaris</i></p> <p>112 Surgical aspects of lower gastrointestinal cancers, 735<br /> <i>Anthony J. Senagore</i></p> <p>113 Surgical aspects of renal cancer, 739<br /> <i>Michael E. Woods and Matthew C. Raynor</i></p> <p>114 Surgical aspects of bladder cancer, 744<br /> <i>Michael B. Williams</i></p> <p>115 Surgical aspects of prostate cancer, 747<br /> <i>Peter Pinto</i></p> <p>116 Surgical aspects of melanoma, 754<br /> <i>Thomas Velancia</i></p> <p><b>PART 10 Multidisciplinary Approach: Consultation with Radiation Oncology Team</b></p> <p>117 Radiotherapy for head and neck cancers, 761<br /> <i>Shiyu Song</i></p> <p>118 Radiotherapy for ductal carcinoma in situ (DCIS), 767<br /> <i>Beryl McCormick</i></p> <p>119 Radiotherapy for early-stage invasive breast cancer, 771<br /> <i>Julia White</i></p> <p>120 Radiotherapy for thoracic malignancies, 778<br /> <i>Meredith E. Giuliani and Andrea Bezjak</i></p> <p>121 Radiotherapy for gastrointestinal malignancies, 785<br /> <i>Manisha Palta, Christopher Willett, and Brian Czito</i></p> <p>122 Radiotherapy for genitourinary malignancies, 789<br /> <i>Christina H. Chapman and Curtiland Deville</i></p> <p><b>PART 11 Hereditary Cancer Syndromes and Genetic Testing in Oncology</b></p> <p>123 When to suspect hereditary cancer syndromes, 795<br /> <i>Emily Dalton and Kathy Schneider</i></p> <p>124 Hereditary breast cancer syndromes, 800<br /> <i>Kathy Schneider and Emily Dalton</i></p> <p>125 Genetic testing in gastrointestinal tumors, 804<br /> <i>Kristen M. Shannon and Daniel C. Chung</i></p> <p>126 Hereditary urogenital cancer syndromes, 810<br /> <i>Melanie Corbman and Eric Fowler</i></p> <p><b>PART 12 Special Issues in Hematology and Oncology</b></p> <p>127 Carcinoma of unknown primary (CUP), 817<br /> <i>Isabella C. Glitza and Gauri R. Varadhachary</i></p> <p>128 Geriatric oncology, 822<br /> <i>Nayana Kamath and Supriya Gupta Mohile</i></p> <p>129 Nuts and bolts of cancer immunotherapy, 826<br /> <i>Christopher R. Heery and James L. Gulley</i></p> <p>130 Controversies related to oncology clinical trial development, 831<br /> <i>Elihu H. Estey</i></p> <p>131 PET scan in oncology, 835<br /> <i>Shaunagh McDermott and Michael A. Blake</i></p> <p>132 Hematopoietic growth factors, 841<br /> <i>LeAnn B. Norris, Jametta Magwood, and Charles L. Bennett</i></p> <p>133 Anticoagulation issues in oncology, 844<br /> <i>Steven M. Corsello and Jean Marie Connors</i></p> <p>134 Symptom management and palliative care, 851<br /> <i>Rony Dev and Eduardo D. Bruera</i></p> <p>135 Metabolic and nutritional issues in oncology, 860<br /> <i>Julia Fechtner, Carolyn Lammersfeld, Carol Ireton-Jones, and Pankaj Vashi</i></p> <p>136 Bone-related issues in oncology, 867<br /> <i>S. Mujtaba Rizvi, Helen Collins, and Alan Lipton</i></p> <p>137 Integrative medicine in oncology, 872<br /> <i>Weidong Lu and David S. Rosenthal</i></p> <p>138 Naturopathic medicine in oncology, 879<br /> <i>Christina M. Shannon, Tracey Thomas, and Shauna Birdsall</i></p> <p>139 Anesthesiology consultation for localized cancer pain, 884<br /> <i>Abed Rahman, Magdalena Anitescu, and Raed Rahman</i></p> <p>140 Musculoskeletal care in oncology, 893<br /> <i>James E. Rosenberg and Charles A. McDonald</i></p> <p>141 Cancer survivorship and psychosocial issues in oncology, 896<br /> <i>Jabeen Abutalib, Shahid Raza, and Laura Sunn</i></p> <p><i>Index, 902</i></p> <p><i>Color plate section facing p.522</i></p>

<p><b>Syed A. Abutalib</b>, MD, is Assistant Director for Stem Cell Transplantation at the Chicago-area branch of Cancer Treatment Centers of America, or CTCA. CTCA is a group of five private treatment centers in the USA focused on patient care in oncology. For several years now, Dr. Abutalib has authored the very popular and well-received "Clinical Conundrums" feature in the oncologist tabloid paper <i>Clinical Oncology</i> (McMahon Publishing), and this is where the idea came to him to enhance and expand his concept from that experience into this book.</p> <p><b>Maurie Markman</b>, MD, is Senior Vice President of Clinical Affairs and National Director of Medical Oncology at Cancer Treatment Centers of America (CTCA). A nationally-renowned oncologist, Dr. Markman has more than 20 years of experience in cancer treatment and gynecologic research at some of the country’s most recognized facilities. Dr. Markman has served as the Vice President for Clinical Research and Chairman of the Department of Gynecologic Medical Oncology at M.D. Anderson Cancer Center in Houston, Texas. Prior to that, Dr. Markman spent 11 years as Chairman of the Department of Hematology/Oncology and Director of the Taussig Cancer Center at the Cleveland Clinic Foundation. He also spent five years as Vice Chairman of the Department of Medicine at Memorial Sloan-Kettering Cancer Center in New York.</p>

US